GlobeNewswire

Hitachi Vantara To Acquire REAN Cloud

Dela

Deal Will Extend Hitachi Vantara's Cloud Portfolio and Managed Services Capabilities To Accelerate Digital Transformations Across Public, Private and Hybrid Cloud Environments

SANTA CLARA, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced its intent to acquire REAN Cloud LLC, a global cloud systems integrator, managed services provider and solutions developer of cloud-native applications across big data, machine learning and emerging internet of things (IoT) spaces.

Founded in 2013, REAN Cloud has quickly been recognized as a leading cloud systems integrator, earning the status of AWS Premier Consulting Partner and Microsoft Azure Silver Partner. REAN Cloud's deep hyperscale expertise and industry-leading infrastructure-as-code REAN Cloud Accelerator Platform enable highly automated, intelligent, scalable and secure cloud adoption and managed services. These services focus on delivering client business outcomes with significantly faster realization of business value. With 47Lining's capabilities (acquired by REAN Cloud last year), REAN Cloud also delivers customized solutions for IoT analytics, predictive analytics and machine learning, allowing customers to more quickly unlock new business opportunities.

This acquisition will reinforce Hitachi Vantara's ability to accelerate secure enterprise cloud adoption across multicloud environments and strengthen its ability to manage and operate traditional applications as well as emerging workloads in artificial intelligence and machine learning. Hitachi Vantara shares REAN Cloud's passion for creating leading-edge solutions and will leverage REAN Cloud's expertise to speed delivery of transformative digital solutions for its combined customers and partners.

"Our global customers across the Hitachi, Ltd., ecosystem are driving their own digital transformations to create competitive advantages in the marketplace," said Brian Householder, chief executive officer of Hitachi Vantara. "Modernized infrastructure running both on and off premises and intelligent data governance and analytics are the foundational pillars of digital transformations. REAN Cloud powerfully extends Hitachi Ltd.'s existing portfolio for customers and partners in these areas."

"Enterprises today want the ultimate flexibility in selecting the right environment for their varied workloads and development requirements. Moving and managing data and applications across environments requires careful orchestration through a unified cloud platform," said Bobby Soni, chief solutions and services officer of Hitachi Vantara. "Hitachi Vantara already offers trusted and reliable private cloud solutions for customers who want pay-as-you-go experiences without having to move their data off premises. With REAN Cloud, we will be able to extend our unified cloud offerings to public and hybrid clouds, and we will enable customers to accelerate their digital transformations by deploying analytics-centric solutions to drive business outcomes."

"When we first founded REAN Cloud, we understood the pivotal role that the cloud would play in transforming the way enterprises do business to reach their goals faster," said Sri Vasireddy, managing partner of REAN Cloud. "As cloud adoption continues its rapid growth worldwide, we are truly excited to join forces with Hitachi Vantara, which shares our focus on shaping the future of digital transformation with innovative solutions. Our team looks forward to evolving REAN Cloud's platform to accelerate customers' outcome-based offerings."

Once the acquisition closes, REAN Cloud's founders will continue to lead and grow the business as an integral part of Hitachi Vantara's Solutions and Services organization, led by Bobby Soni. REAN Cloud customers can expect continued high-quality services through REAN Cloud's existing workforce, enhanced by Hitachi Vantara's global delivery capabilities and leading digital solutions.

The transaction is expected to close later this year, subject to customary closing conditions and regulatory approvals. Financial terms of the deal are not being disclosed.

Citi acted as the exclusive financial advisor to Hitachi Vantara and William Blair and MVP acted as financial advisors to REAN Cloud.

For more information about Hitachi Vantara's intent to acquire REAN Cloud, read the blog post from Bobby Soni: https://www.hitachivantara.com/blog/a-clear-view-of-the-clouds/.

About REAN Cloud
REAN Cloud, a global cloud systems integrator and Managed Service Provider (MSP), is a Premier Consulting Partner in the Amazon Web Services (AWS) Partner Network (APN) and a Microsoft Azure Silver Partner. REAN Cloud offers managed and professional services and solutions for hyperscale integrated IaaS and PaaS providers and is one the few systems integrators capable of supporting the entire cloud services life cycle. Backed by extensive security DNA and deep compliance IP and expertise, REAN Cloud specializes in helping enterprise customers that operate in highly regulated environments - Financial Services, Healthcare/Life Sciences, Education and the Public Sector - to get the most from their cloud investment while enabling them to accelerate the value gained from the cloud once there. REAN Cloud's team has worked with global organizations, including the American Heart Association, Alexion Pharmaceuticals, Ditech Mortgage, Ellucian, Globus Genomics, Philips, PierianDx, SAP, Symantec, Teradata and Veritas. REAN Cloud solutions are bundled with advanced security features to help address clients' compliance needs.

About Hitachi Vantara
Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd., helps data-driven leaders find and use the value in their data to innovate intelligently and reach outcomes that matter for business and society. The company combines technology, intellectual property and industry knowledge to deliver data-managing solutions that help enterprises improve their customers' experiences, develop new revenue streams, and lower the costs of business. Only Hitachi Vantara elevates your innovation advantage by combining deep information technology (IT), operational technology (OT) and domain expertise. The company's experts work with organizations everywhere to drive data to meaningful outcomes. Visit us at www.hitachivantara.com.

About Hitachi, Ltd.
Hitachi, Ltd. (TSE:6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.

HITACHI is a trademark or registered trademark of Hitachi, Ltd. All other trademarks, service marks, and company names are properties of their respective owners.

 

Company Contact

Mary Ann Gallo
Hitachi Vantara
Mary.ann.gallo@hitachivantara.com
408-970-7932



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hitachi Vantara via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum